The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

The approval was based on data from the POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of ...

The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol ...

There’s a newly approved treatment for multiple myeloma that has returned after earlier therapy. The combination of Tecvayli ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide) for ...

The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...

Bristol Myers Squibb Company on Friday won U.S. approval for its oral drug Sotyktu to treat adults with active psoriatic arthritis. The decision gives patients another option for joint and skin ...

Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...

Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based ...

FDA approval introduces first-in-class, once-daily oral TYK2 inhibition for active psoriatic arthritis, expanding deucravacitinib beyond its 2022 plaque psoriasis indication. POETYK PsA-1 and PsA-2 ...